PAREXEL

Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer

Retrieved on: 
Monday, May 1, 2023
University, Verastem Oncology, PAREXEL, Wall Street, Cognition, Bangladesh Technical Education Board, University of Massachusetts Boston, SVP, Therapy, Hologic, Management, Science

PURCHASE, N.Y. , May 01, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), today announced the appointment of John Doyle to the role of chief financial officer.

Key Points: 
  • PURCHASE, N.Y. , May 01, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), today announced the appointment of John Doyle to the role of chief financial officer.
  • Mr. Doyle has substantial experience leading and managing financial operations at development- and commercial-stage public life sciences companies through financings, mergers, acquisitions and licensing agreements.
  • “John has significant experience raising capital in challenging markets and leading companies through the evolution to commercialization.
  • Mr. Doyle was most recently chief financial officer of 4D Pharma plc, and previously was SVP and chief financial officer of Chiasma Inc. During his tenure at Chiasma Inc, the company began reporting commercial sales and ultimately completed a merger with Amryt Pharma.

Chain Pharmaceuticals GmbH Announces Its Phytocannabinoid Drug Discovery Platform

Retrieved on: 
Tuesday, November 15, 2022
Curia, Intel Corporation v. CPM United Kingdom Ltd., Union, AI, Pharmacology, Doctor of Philosophy, Machine learning, EMA, Artificial intelligence, Algorithm, Patient, Intel, CIO, Cannabis, GDPR, PAREXEL, Medicine, CHMP, Drug development, Research, Charles University, Cannabinoid, AM, Intelligence, Entrepreneurship, Health, Drug discovery, Acquisition, Pharmaceutical industry, Medical device, MD, Ematheudes neurias

FRANKFURT AM MAIN, Germany, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Dr. Pierre Debs, Ph.D. announced today the launch of Chain Pharmaceuticals GmbH, a phytocannabinoid drug discovery company leveraging machine learning and real world medical data in the development of clinically proven plant-based medicines for market authorization.

Key Points: 
  • FRANKFURT AM MAIN, Germany, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Dr. Pierre Debs, Ph.D. announced today the launch of Chain Pharmaceuticals GmbH, a phytocannabinoid drug discovery company leveraging machine learning and real world medical data in the development of clinically proven plant-based medicines for market authorization.
  • Clinically proven market authorized medications are sine qua non for long-term demands of all stake-holders throughout European healthcare systems, explains Dr. Pierre Debs, Founder and Chief Executive Officer of Chain Pharmaceuticals GmbH.
  • Chain Pharmaceuticals patient data-gathering app, HealChain, is designed with Innoplexus app and its capabilities of data extraction with AI algorithms.
  • Chain Pharmaceuticals GmbH is a German-based drug discovery company using real world data, machine-learning and artificial intelligence to rapidly design and execute clinical trials leading to market-authorized phytocannabinoid products.

Reinhold Schulz Joins Flourish Research as Chief Executive Officer

Retrieved on: 
Monday, August 15, 2022
Physiology, Medicine, Industry, CNS, NEW, Growth, CRO, Arizona State University Downtown Phoenix campus, Knowledge, Research, Patient, Diversified Pharmaceutical Services, PPD, Business administration, Head, Vaccine, University, Clinical trial, Biochemistry, PAREXEL, Solution, Master of Business Administration, Pharmaceutical industry, Science, Pharmacology, Chemistry

NEW YORK, Aug. 15, 2022 /PRNewswire-PRWeb/ -- Reinhold Schulz has been named Chief Executive Officer of Flourish Research, a company designed to acquire, operate, and integrate the best clinical research sites in North America. Flourish operates large, best-in-class sites with experience in Phases I-IV and investigators with deep expertise in key therapeutic areas.

Key Points: 
  • Reinhold Schulz joins Flourish Research as Chief Executive Officer.
  • NEW YORK, Aug. 15, 2022 /PRNewswire-PRWeb/ -- Reinhold Schulz has been named Chief Executive Officer of Flourish Research, a company designed to acquire, operate, and integrate the best clinical research sites in North America.
  • Prior to Accelerated Enrollment Solutions, Reinhold served as Head of Early Phase Development clinical research sites at PPD.
  • Flourish key investigators are full-time, dedicated to research at sites that are large and highly experienced.

500+ Gather in Amsterdam for Euro Convergence, RAPS’ Largest-Ever European Event

Retrieved on: 
Thursday, May 12, 2022
RAPS, Royal commission, NAMSA, Education, Food, US Food Sovereignty Alliance, PAREXEL, Medicines and Healthcare products Regulatory Agency, Â, European Commission, European Medicines Agency, IVD, Health, MHRA, BSI, Health care, EC, Research, FDA, Industry, EMA, Euro, RAC, Medication, Publication, GLOBE, Video game, Medical device, Security (finance), EU, Swissmedic, MD

Euro Convergence is the premier annual event for European regulatory professionals.

Key Points: 
  • Euro Convergence is the premier annual event for European regulatory professionals.
  • This years Euro Convergence also offered the European regulatory community a long-awaited opportunity to once again meet in person to discuss issues, share ideas and network.
  • The European regulatory community is still navigating extensive changes to EU regulations even as we continue to address urgent pandemic-related healthcare needs.
  • The fact that it has been RAPS largest-ever European conference is a testament to the vibrance and dedication of the regulatory community.

Curebase Adds Pharma, Clinical Research Veteran to Advisory Board

Retrieved on: 
Thursday, May 12, 2022
Physician, Population, Pharmacology, ICON, PAREXEL, Lviv, Patient, Master, Associate, Clinical trial, COVID-19, Advisory board, Uppsala University, Research, SAN, Cros, Partnership, CRO, DCT, Technology, Lund University, Infant, Eriksson, CEO, Pharmaceutical industry, Pacific Ocean

The Curebase platform and services empower sponsors, and physicians from practices of all sizes to conduct clinical research, including private practices, independent clinics, and large academic research sites.

Key Points: 
  • The Curebase platform and services empower sponsors, and physicians from practices of all sizes to conduct clinical research, including private practices, independent clinics, and large academic research sites.
  • A four-decade veteran of the pharmaceutical and clinical research industries, Eriksson is head of clinical development at Infant Bacterial Therapeutics AB in Stockholm, Sweden, where he manages and coordinates clinical research operations globally.
  • He was a seniorexecutive at MerckCo., Inc., where he served foralmost 30 years, specializing in clinical pharmacology,clinical research and clinical research operations worldwide.
  • By applying cutting edge clinical software and remote study management techniques to the problem, we are reinventing clinical trials and research from the ground up.

BrainsWay Appoints Dr. Joachim Seidel as Vice President of Corporate Development and Strategy

Retrieved on: 
Monday, March 28, 2022
TASE, Company, Private Securities Litigation Reform Act, Psychiatry, NASDAQ, Tissue engineering, Materials science, EV3, Biomedical engineering, Growth, Legislation, Lists of diseases, Tic disorder, Brainsway, Covidien, Research, Swiss Federal Institute of Aquatic Science and Technology, Medtronic, PAREXEL, Science, Health, Failure, Corporate development, Industry, Technology, Knowledge, Review, U.S. Securities and Exchange Commission, Deep, ETH Zurich, TMS, Doctor of Philosophy, Transcranial magnetic stimulation, GLOBE, News, Addiction, Awareness, FDA, Insurance, Acquisition, Swiss Federal Institute of Technology, Johnson & Johnson, MIT, Management, Medical device, Pharmaceutical industry, Medicare

and JERUSALEM, March 28, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Joachim Joe Seidel, Ph.D., to the newly created position of Vice President of Corporate Development and Strategy.

Key Points: 
  • and JERUSALEM, March 28, 2022 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (BrainsWay or the Company), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Joachim Joe Seidel, Ph.D., to the newly created position of Vice President of Corporate Development and Strategy.
  • Dr. Seidel has more than 20 years of experience in the medical device industry and has held positions in business development, corporate strategy, program management, and research and development.
  • I am thrilled to join BrainsWay at such an exciting time in its corporate evolution, commented Dr. Seidel.
  • Prior to this, Dr. Seidel held corporate development and strategy roles at Covidien, Medtronic, and PAREXEL.

RAPS Euro Convergence Features Speakers From EMA, FDA, and Swiss, Austrian and UK Health Authorities, as well as Notified Bodies

Retrieved on: 
Thursday, March 24, 2022
Medicines and Healthcare products Regulatory Agency, NAMSA, Medication, BSI, Public health, European Medicines Agency, Health care, RAPS, Research, Publication, PAREXEL, RAC, MHRA, US Food Sovereignty Alliance, Lists of television programs, Euro, GLOBE, EMA, FDA, Education, Medical device, Pharmaceutical industry, Swissmedic, MD

The annual three-day conference devoted to European healthcare product regulations and regulatory issues will take place, 1012 May in Amsterdam.

Key Points: 
  • The annual three-day conference devoted to European healthcare product regulations and regulatory issues will take place, 1012 May in Amsterdam.
  • More than 120 expert speakers will provide updates and insights on important European regulatory topics.
  • More than 30 represent health authorities, including FDA, EMA, Swissmedic, the Austrian Medicines and Medical Devices Agency, the UKs Medicines and Healthcare products Regulatory Agency (MHRA), or notified bodies, BSI, TV SD and Dekra.
  • This conference is critical for continued dialogue among health authorities, notified bodies and regulated industry.

North America ePRO, ePatient Diaries, and eCOA Market Report 2021: Increasing Demand for EHRs, Rising Use of Smartphones, Growing Demand for Clinical Trials - Forecast to 2028 - ResearchAndMarkets.com

Retrieved on: 
Monday, March 21, 2022
Technology, Health, Data Management, Other Health, Drug development, ERT, CAGR, Kane Epati, Guest appearance, Growth, Clinical trial, Nursing, Compliance, Research, PAREXEL, Health information management, Privacy, Confidentiality, ECOA, Industry, Laika (EHR testing framework), Technology, ICON, Academic institution, Others, Data collection, Type, COVID-19, Computer, EPRO, Efficiency, Patient, Collection, Pharmaceutical industry, Medical device, Shadow King, Modality, Hospital

The report provides trends prevailing in the North America ePRO, ePatient Diaries, and eCOA market along with the drivers and restraints pertaining to the market growth.

Key Points: 
  • The report provides trends prevailing in the North America ePRO, ePatient Diaries, and eCOA market along with the drivers and restraints pertaining to the market growth.
  • However, the market is expected experiencing slow growth during the forecast period owing to the concerns regarding data privacy.
  • These factors had a potential impact on the North America ePRO, e-Patient Diaries, and eCOA market.
  • In 2020, the eCOA (Electronic Clinical Outcome Assessments) segment accounted for the North America ePRO, ePatient diaries, and eCOA market's largest market share.

Applied Molecular Transport Appoints Industry Veteran Carolyn Finkle as Senior Vice President, Head of Regulatory Affairs

Retrieved on: 
Monday, March 14, 2022
AMTI, Nasdaq, Securities Act of 1933, Head, GMP, IE, Catalent, University, Pharmacovigilance, Rheumatoid arthritis, AMT, Inflammation, U.S. Securities and Exchange Commission, Medicago, Magazine, PERI, Health minister, PAREXEL, Autoimmunity, Inflammatory Bowel Diseases, University of Ottawa Heart Institute, Securities Exchange Act of 1934, Research institute, National Institute of Pharmaceutical Education and Research, Hajipur, Bachelor of Science, GLOBE, Master of Science, Georgetown University Graduate School of Arts and Sciences, Patient, Security (finance), MedImmune, CA, Growth, Disease, SEC, Program, Terminology, SAN, Management, Pharmaceutical industry, Chemistry, UC

SOUTH SAN FRANCISCO, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Carolyn Finkle as senior vice president, head of regulatory affairs. She becomes a member of the AMT executive leadership team, reporting to chief executive officer and co-founder of AMT, Tahir Mahmood, Ph.D.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced the appointment of Carolyn Finkle as senior vice president, head of regulatory affairs.
  • Ms. Finkle joins with more than thirty years of experience leading regulatory strategy, product development and product approvals for global biotechnology organizations.
  • Most recently, Ms. Finkle served as chief operating officer and head of regulatory affairs at Medicago.
  • Ms. Finkle also previously held leadership roles in regulatory affairs and product development for Catalent, MedImmune, PAREXEL and Celsion.

Parexel and n-Lorem Foundation Partner to Support Development of New Investigational Therapies for Nano-rare Patients

Retrieved on: 
Wednesday, February 23, 2022
Biotechnology, Other Health, Health, Philanthropy, General Health, Pharmaceutical, Other Philanthropy, Research, Fund Raising, Foundation, Science, Therapy, Health, Partnership, ASO, Twitter, Efficiency, Degenerative disease, Time, RNA, Disease, Trial of the century, Hope, LinkedIn, DNA, Ionis Pharmaceuticals, Natural history, Leadership, Life, FDA, Instagram, YouTube, Patient, CRO, CEO, Fine chemical, Pharmaceutical industry, Medicine, Facebook, Parexel, Parexel, n-Lorem, PAREXEL, N-LOREM

Currently, n-Lorem has over 50 nano-rare patients and each patient requires both an individual natural history study and a clinical study.

Key Points: 
  • Currently, n-Lorem has over 50 nano-rare patients and each patient requires both an individual natural history study and a clinical study.
  • n-Lorem and Parexel demonstrate a shared passion and commitment to making a difference for nano-rare patients, said Jamie Macdonald, CEO at Parexel.
  • Drug development for rare diseases is complex and presents many challenges, added Clare Grace, Ph.D. Chief Patient Officer at Parexel.
  • Partnering with Parexel will allow us to expand our clinical research infrastructure, broadening access to n-Lorem for nano-rare patients.